Advertisement Zynex wins CE marking for NeuroMove and TruWave devices - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Zynex wins CE marking for NeuroMove and TruWave devices

Zynex, a provider of pain management systems and electrotherapy products for medical patients with functional disability, has received CE marking for its NeuroMove and TruWave devices for sales in Europe.

Both NeuroMove and TruWave devices have previously received the FDA’s clearance for marketing in the US.

NeuroMove is marketed for stroke and spinal cord injury rehabilitation and TruWave is an electrotherapy device.

Thomas Sandgaard, CEO of Zynex, said: “The CE marking allows us to sell these products in the EU and we also anticipate it will help the process of regulatory approval in many other countries outside of Europe.”